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SUMMARY 
The germline encoded proteins serving as “pattern recognition receptors” (PRRs) constitute the 
earliest step in the innate immune response by recognizing the “pathogen-associated molecular 
patterns” (PAMPs) that comprise microbe nucleic acids and proteins usually absent from healthy 
hosts. Upon detection of exogenous nucleic acid two different innate immunity signaling cascades 
are activated. The first culminates in the production of chemokines, cytokines, and type I 
interferons (IFN-I), while the second leads to inflammasome complex formation. Human 
cytomegalovirus (HCMV), a member of the -herpesvirus subfamily, is a wide spread pathogen 
that infects a vast majority of the world’s population. The virion has an icosahedral capsid that 
contains a linear dsDNA genome of approximately 240 kb, surrounded by an outer lipid envelope 
and a proteinaceous tegument containing several viral proteins. Despite the numerous and 
multifaceted antiviral effects of IFNs and cytokines, HCMV is able to invade, multiply, and 
establish persistent infection in healthy human hosts. To achieve this goal the virus has developed 
different strategies to block the IFN-I response and to alter the physiological outcomes of the IFN-
inducible genes. This article focuses on HCMV tegument pp65 by reviewing its mechanisms of 
action in favoring virus evasion from the host innate immune response.
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The innate immune response is the first line of defense against human cytomegalovirus 
(HCMV) and allow the host to rapidly mount antiviral measures (La Rosa and Diamond, 2012; 
Paludan, 2015). This becomes particularly evident during the perinatal period, because of the 
immaturity of adaptive immunity (Gibson et al., 2007; La Rosa and Diamond, 2012). The innate 
immune responses include type I and III interferons, and inflammatory cytokines that immediately 
set up an antiviral state and initiate an inflammatory response. Innate immunity to virus infection 
involves recognition of pathogen-associated molecular patterns (PAMPs), or damage-associated 
molecular patterns (DAMPs), by germline-encoded molecules termed pattern recognition receptors 
(PRRs), able to distinguish ‘self’ from ‘non-self’. During virus infection, viral DNA and RNA are 
detected by a myriad of PRRs whose activation elicits antiviral responses and inflammation 
(Hoffmann et al., 2015). Generally, these PRRs can be divided into two main categories depending 
on their subcellular location. PRRs that recognize extracellular PAMPs are essentially found on the 
plasma or endosomal membranes, and include the Toll-like receptors (TLRs) and the C-type lectin 
receptors (CLRs) (Takeuchi and Akira, 2010; Dambuza and Brown, 2015). These membrane-bound 
PRRs are largely expressed by antigen presenting cells, such as macrophages and dendritic cells. By 
contrast, intracellular PRRs are found in the cytoplasm or nucleus of mammalian cells, and include 
the NOD-like receptors (NLRs) (Kim et al., 2016), RIG-I (retinoic acid-inducible gene I)-like 
receptors (RLRs) (Loo and Gale, 2011), and a group of intracellular DNA sensors such as cyclic 
GMP/AMP (cGAMP) synthase (Chen et al., 2016) and interferon-γ-inducible protein 16 (IFI16) 
(Dell’Oste et al., 2015). Upon the detection of viral pathogens, the PRRs trigger a series of events 
whose outcome is the activation of various transcriptional factors, including MAP kinases 
(MAPKs), nuclear factor-κB (NF-κB), interferon regulatory factor 3 (IRF3), and IRF7, required for 
the transcriptional induction of type I interferon (IFN-I) and the release of pro-inflammatory 
chemokines to drive immune cells to the site of infection (Mogensen, 2009; Hoffmann et al., 2015). 
Prointerleukin-1β (pro-IL-1β) and prointerleukin-18 (pro-IL-18) are chief products of PRRs 
activation, but need to be processed into their functional forms prior to be released from cells 
through multiprotein complexes known as inflammasomes (Lupfer et al., 2015). Inflammasomes 
come in many forms and are also mainly activated following recognition of PAMPs (Guo et al., 
2015). The common inflammasome platform consists of an inflammasome sensor molecule, an 
adaptor protein known as ASC (adaptor apoptosis-associated speck-like protein containing a 
CARD), and a CARD domain containing pro-caspase-1 (Latz et al., 2013). Inflammasome complex 
assembly results in caspase-1 activation and cleavage of pro-IL-1β and pro-IL-18, leading to their 
activation and release from cells (Lupfer et al., 2015). 
THE HUMAN CYTOMEGALOVIRUS 
HCMV, the prototype member of the β-herpesvirus subfamily, is an enveloped virus, with a double-
stranded DNA genome, packaged in an icosahedral capsid, consisting of 162 capsomere subunits. 
The tegument is a protein-rich layer between the capsid and the envelope, containing 50% of the 
total viral proteins of the virion (Figure 1), including a 65-kilodalton (kDa) phosphoprotein (pp) 
referred to as pp65 (pUL83), one of the dominant targets of the immune response to infection 
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(Landolfo et al., 2003; Maxwell and Frappier, 2007; Kalejta, 2008; Tandon and Mocarski, 2012; 
Smith et al., 2014; Griffiths et al., 2015). HCMV slowly grows in cell cultures, displaying a 
characteristic tissue-specific (blood vessel, lungs, liver, kidney, intestine), strict species-specific 
tropism, and a broad cell tropism for fibroblasts, epithelial, endothelial, smooth muscle, and 
myeloid cells (Sinzger et al., 1995; Sinzger et al., 2008; Li and Kamil, 2015). Following primary 
infection, it establishes a life-long latency in myeloid cells of the bone marrow and then periodically 
reactivates (Reeves and Sinclair, 2013; Dupont and Reeves, 2016). 
HCMV is worldwide distributed, with a seroprevalence ranging from 45 to 100% that is 
likely to be highest in countries of lower socioeconomic conditions (Cannon, 2009; Cannon et al., 
2010). The vast majority of infections are asymptomatic or self-limited in immunocompetent 
individuals, whereas in immunocompromised hosts and infected fetuses, HCMV produces a high 
burden of disease (Navarro, 2016). HCMV infection is one of the most common congenital 
infections worldwide. Its rate in developed countries is estimated to average from 0.6 to 0.7% of all 
live births, and approximately 60,000 newborns per year are HCMV positive in the United States 
and the European Union combined (Manicklal et al., 2013; Marsico and Kimberlin, 2017). 
Symptomatic infections are characterized by mild neurological impairment or deafness, blindness, 
mental retardation, and premature death (Britt, 2017). Importantly, HCMV is also the most 
prevalent viral agent in transplant settings with symptomatic infections occur in 20-60% of 
transplant patients (Brennan, 2001). Patients acquire HCMV from reactivation of latent virus or 
donor-transmitted virus, leading to impaired graft survival, graft-versus-host disease, and other 
opportunistic infections such as invasive fungal infections (Kaminski and Fishman, 2016). These 
patients can also develop life-threatening, multi-organ infectious disease, as the virus disseminates 
to the lung, liver, pancreas, kidney, stomach, intestine, brain, and parathyroid glands (Potena et al., 
2016; Camargo and Komanduri, 2017; López-Botet et al., 2017). HCMV causes severe disease in 
AIDS patients, including retinitis, gastrointestinal disease, and encephalitis (Shinkai et al., 1997; 
Sissons and Wills, 2015). Moreover, its association with other syndromes has been reported, such 
as inflammatory bowel disease (Sager et al., 2015; Siegmund, 2017), Alzheimer’s disease (Harris 
and Harris, 2015), new-onset diabetes, hypertension, immunosenescence, and atherosclerosis 
(Einollahi et al., 2014; Halenius et al., 2014; Wang et al., 2017). Finally, a link between HCMV 
and several human cancers, such as glioblastoma and breast cancer has been suggested (Söderberg-
Nauclér, 2006; Herbein and Kumar, 2014; Richardson et al., 2015; Quinn et al., 2016; Foster et al., 
2017). Nonetheless, it remains elusive whether HCMV is the causative agent or a bystander in these 
diseases. 
The HCMV pp65 (pUL83) 
The tegument of HCMV and other herpesvirus virions is a unique proteinaceous layer 
located between the lipid envelope and the capsid (Kalejta, 2008). In these last few years, the 
generation of mutant viral strains by BAC technology and the improvement of microscopy 
techniques offered the chance to better understand the role of tegument proteins in the context of 
HCMV replication (Smith et al., 2014). For example, the tegument is generally defined as an 
unstructured and amorphous layer, but recent cryo-electron microscopy studies allowed dissecting 
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defined structures inside the HCMV nucleocapsid proximal inner, with the binding of tegument 
proteins to the protein capsid (Chen et al., 1999). Of the 71 viral proteins found within infectious 
virions, over one-half are tegument components, 10 of which are conserved across herpesviruses 
(Varnum et al., 2004) (Figure 1).  
pUL83 (also known as phosphoprotein pp65) is the HCMV most abundant tegument protein 
and the major constituent of extracellular particles (>2,000 copies per mature virion) (Irmiere and 
Gibson, 1983; Varnum et al., 2004). Like the other nuclear tegument proteins, pp65 traffics to the 
nucleus of permissively infected cells after fusion of the viral and cellular membranes immediately 
after entry, and then relocalizes to the cytoplasm at the later stages of infection (Schmolke et al., 
1995; Sanchez et al., 2000). While initial viral growth experiments using pp65-deletion mutants 
demonstrated pp65 is not essential for viral replication in vitro and for the production of new 
infectious virus particles (Schmolke et al., 1995), cumulative evidence points that pp65 is important 
for efficient growth in both monocyte-derived macrophages and fibroblasts (Chevillotte et al., 2009; 
Becke et al., 2010; Cristea et al., 2010). The primary cause of this growth defect likely involves 
impaired pp65 functions during the initiation of infection as well as regulation of pp65 localization 
(Smith, 2014). Accordingly, it has been demonstrated that disruption of pp65 expression can 
influence the incorporation of viral proteins into the virion tegument, such as pUL25, ppUL97 and 
ppUL69, by direct or indirect binding, suggesting that pp65 is part of a complex protein interaction 
network that may be crucial for assembly (Kamil and Coen, 2007; Chevillotte et al., 2009; To et al., 
2011). In spite of these modifications in the tegument composition, the virion particles are 
comparable to the wild type virus, except for the absence of dense bodies. However, it remains to be 
definitively established if the defect in replication of the pp65 mutant virus in vitro is due to the 
absence of pp65 per se, or to the lack of important viral proteins such as ppUL97 and ppUL69 
during the initial stages of replication (Kamil and Coen, 2007; Chevillotte, 2009; To et al., 2011). 
Recently, pp65 protein sequence and its posttranslational modifications (PTMs) have been 
characterized (Li et al., 2013). The protein displays a bipartite structure, organized in a conserved 
N-terminal domain (~386 residues), a divergent linker region, and a conserved C-terminus (CTD, 
~90 residues) (Figure 2). pUL83 is known to be phosphorylated (Roby and Gibson, 1986); 
however, the phosphorylation sites have been just recently defined, after isolation of the virally or 
ectopically expressed pUL83 from human fibroblasts followed by mass spectrometry analyses. 
Eight phosphorylated serine (S) or threonine (T) residues present in both virally and ectopically 
expressed pUL83, and two sites (T32 and S472) detected only in the latter were identified, 
suggesting that most phosphorylations are regulated by host kinases. Notably, most sites are within 
the linker, with S406, T468, and S472 present at casein kinase II-like motifs (S/TXXE/D) (Li et al., 
2013). Phosphorylation is directly involved in regulating the localization of pp65 during infection. 
It has been demonstrated pp65 can shuttle in and out from the nucleus with export in a CRM1 
dependent manner (Prichard et al., 2005; Frankenberg et al., 2012), with many tegument proteins 
such as ppUL69, pUL35, pTRS1 and pUL96 functioning as shuttling protein (Blankenship and 
Shenk, 2002; Schierling et al., 2005; Toth and Stamminger, 2008; Tandon and Mocarski, 2012). It 
is possible that phosphorylation of pp65 also plays a role in regulating the localization of this 
protein during HCMV repliaction. For example, pp65 phosphorylation by ppUL97 regulates pp65 
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redistribution to the AC at the later stages of infection (Prichard et al., 2005; Becke et al., 2010). 
These findings are supported by experiments with CDK inhibitors, that affect both the 
phosphorylation and localization of pp65 (Sanchez et al., 2007). One possible explanation of these 
data is that phosphorylation of pp65 by ppUL97 blocks recognition of the nuclear localization 
signals, resulting in a change in distribution to the cytoplasm (Smith et al., 2014). A useful model to 
understand the impact of pp65 phosphorylation on its localization is the RV-VM1 mutant virus, 
containing a 30 amino acid insertion within the pp65 open reading frame (amino acid 387, in 
relatively close proximity to the pp65 nuclear localization signals) (Becke et al., 2010). This virus 
displays a pp65 protein retained in the nucleus at the late stages of infection, resulting in 
accumulation of the MCP and large globular structures within the nucleus, enriched of pp65 and 
ppUL69 proteins, but with a reduced numbers of C-capsids in the cytoplasm, and a lack of dense 
body formation. Consequently, a different pattern of phosphorylation may result in an active 
nuclear localization signal that trigger accumulation and aggregation of the protein in the nucleus. 
Interestingly, two phosphorylation sites were also clustered in the amino terminus in proximity to 
the self-interaction domain, suggesting that phosphorylation also regulates this behavior of pp65. 
These data are definitely consistent with the large aggregates of pp65 that occur in the absence of 
ppUL97 activity (Prichard et al., 2005; Smith et al., 2014). 
The most enigmatic characteristic assigned to pp65 is its kinase activity. Early on, it was 
discovered that virion-associated kinase activity (Mar et al., 1981) is diminished in the UL83-null 
virus (Michelson et al., 1984; Schmolke et al., 1995), indicating a pp65-associated kinase activity. 
However, it was not fully understood if pp65 owns an intrinsic kinase activity (Yao et al., 2001) or 
associates with cellular kinase (Gallina et al., 1999) inside HCMV virions. The putative kinase 
domain of pp65 shows indeed only poor homology with other kinases (Yao et al., 2001). Therefore, 
it is possible that the kinase activity observed in immunoprecipitates with pp65 antibodies might not 
result from an intrinsic kinase activity of pp65 itself but rather from a copurification with other 
cellular or viral kinases. Consistently, pp65 has been found in association with viral UL97 protein 
kinase (Kamil and Coen, 2007), and the cellular proteins polo-like kinase 1 (Plk1) and casein kinase 
II, that have also been found in wild type, but not UL83-null virions (Gallina et al., 1999; Nogalski 
et al., 2007). Accordingly, recombinant pp65 protein autophosphorylates and phosphorylates casein 
in vitro on threonine residues only, and a mutation of the predicted catalytic lysine (K436N) 
abolished this kinase activity (Yao et al., 2001).  
pp65 and innate immunity modulation 
pp65 is responsible for modulating/evading multiple levels of host cell immune surveillance 
during HCMV infections in at least three different ways (McCormick and Mocarski, 2007; Kalejta, 
2008): i) blocking antigen presentation (Gilbert et al., 1996; Odeberg et al., 2003); ii) modulating 
the natural killer cells (Arnon et al., 2005); iii) suppressing the induction of antiviral cytokines 
(Browne and Shenk, 2003; Abate et al., 2004).  
First, the capability of pp65 to prevent major histocompatibility complex (MHC) 
presentation of IE antigens at the start of HCMV infections appears to be dependent on its kinase 
activity. It was shown that pp65 mediates the phosphorylation of viral IE proteins, which blocks 
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their presentation to the MHC class I molecules (Gilbert et al., 1996). The kinase activity of pp65 
has also been implicated in causing the degradation of the alpha chain in the MHC class II cell 
surface receptor, HLA-DR, via an accumulation of HLA class II molecules in the lysosome (Gilbert 
et al., 1996). Furthermore, several studies have presented evidence that pp65 is involved in 
mediating a decrease in the expression of MHC class II molecules (Odeberg et al., 2003). 
Another crucial role of pp65 in immune evasion during HCMV infections is through the 
inhibition of NK cell cytotoxicity (Arnon et al., 2005; Rölle and Brodin, 2016). In detail, pp65 can 
act as an antagonistic ligand that can bind to the NKp30 activating receptor to protect the killing of 
infected cells as well as interfere with the ability of NKp30 to cross-talk between other natural killer 
cells and dendritic cells (Arnon et al., 2005; Arnon et al., 2006). Moreover, pp65 has been shown to 
impair host innate immunity by modulating the interferon response and the inflammasome system 
(Figure 4) (Browne and Shenk, 2003; Abate et al., 2004; Li et al., 2013; Huang et al., 2017). This 
point will be discussed in more details in the following section. 
Third, viruses and their host exert a constant evolutionary pressure on each other, leading to 
mutual adaptation. As an example of pathogen-host co-evolution, AIM2-like receptors (ALR) loci 
in different mammals are quite distinct and AIM2 and IFI16 appear to have evolved adaptively in 
primates (Cagliani et al., 2014), suggesting a strong selective pressure (Brunette et al., 2012). 
Similarly, HCMV has evolved strategies to evade detection by ALRs, mainly by the HCMV 
tegument protein pp65. It has been demonstrated that early during infection, pp65 suppresses IFI16 
mediated detection of HCMV genomic DNA in the nucleus by binding to the IFI16 pyrin (PY) 
domain through its own pyrin association domain (PAD), thus preventing IFI16 oligomerization (Li 
et al., 2013). Moreover, previous reports (Cristea et al., 2010; Gariano et al., 2012) have shown that 
very early during infection, pp65 and IFI16 interact at the viral major immediate-early promoter 
(MIEP), triggering an increase in IE protein expression, which is accompanied by a concomitant 
decrease in antiviral cytokine production. MIEP activation could be NF-κB mediated, because four 
NF-κB responsive elements are present on the MIEP. Moreover, a functional analysis of the ICAM-
1 promoter by deletion- or site-specific mutagenesis has indeed demonstrated that NF-kB is the 
main mediator of IFI16-driven gene induction (Caposio et al., 2007), supporting the hypothesis of a 
ternary interactome (i.e. pp65/IFI16/NF-kB) at the MIEP promoter (Figure 3).  
During the late stages of HCMV infection, a different scenario was observed. First of all, 
consistent with the above reported observations, an increase in IFI16 expression during the early 
events of HCMV replication has been described also by Biolatti et al. (2016), confirming that 
HCMV fosters IFI16 expression with the aim of stimulating IE gene expression at the beginning of 
infection (Biolatti et al., 2016). Of note, the interplay between pp65 and IFI16 was not limited to 
the very early stage of infection but remained functionally relevant throughout the later stages of 
viral replication, including the central process of viral DNA synthesis. In this case, the outcome of 
IFI16/pp65 interaction is downregulation, instead of upregulation, of the UL54 gene promoter, as 
shown by experiments performed with pp65 mutant viruses (Biolatti et al., 2016). Interestingly, at 
later time points of HCMV infection, IFI16 is stabilized by pp65, and delocalized from the nucleus 
to the cytoplasm, to be finally entrapped within newly egressing virions (Biolatti et al., 2016). 
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Overall, these date confirm and expand the role of IFI16 as a restriction factor for HCMV 
replication and of pp65 as HCMV evasion mechanism from innate immune response (Figure 3). 
 
pp65 and IFN signaling. The IFN system is one of the key component against HCMV infection; 
conversely, HCMV, like other herpesviruses, encodes viral factors to counteract IFN pathway, even 
if the exact mechanisms HCMV relies on are only partially defined (Marshall and Geballe, 2009). 
Results obtained by different groups (Browne and Shenk, 2003; Abate et al., 2004; Li et al., 2013), 
including those from our lab (unpublished results), and different approaches, such as RT-qPCR, 
ELISA, and DNA array analysis demonstrated that the HCMV tegument protein pp65 is the main 
inhibitor of IFN-I expression, even if recently also pp71 has been recognized to neutralize IFN 
release (Fu et al., 2017). However, it is still matter of debate, at which level pp65 counteracts IFN 
activation. First of all, one of the main target of pp65 is IRF3, a key component of IFN pathway 
because it induces IFN-β synthesis at the transcriptional level (Abate et al., 2004). In the milestone 
paper from Abate et al. (2004), the use of a deletion mutant HCMV strain unable to express pp65 
resulted in a greater induction of an IFN-like transcriptional profile after HCMV infection, 
conforming the inhibitory activity of pp65 (Abate et al., 2004). The hypothesis that IRF3 could be 
the target of pp65 has been supported by the observation that in the first few hours after infection 
with the pp65-mutant, but not with wild type virus, IRF3 was converted in the 
hyperphosphorylated-active form and then translocated to the nucleus of human fibroblasts or 
PBMC. Moreover, transduction of pp65 alone into human fibroblasts blocked nuclear translocation 
of IRF3 following an activating stress (Abate et al., 2004) (Figure 4). In contrast, the activation of 
NF-κB, another transcriptional activator of IFN, was pp65-independent, as suggested by the 
observation that it relocalized to the nucleus of cells by either wild type or pp65-deleted virus. 
Altogether, these data support the ability of pp65 to block IRF3 activation, by acting in at least two 
different ways: i) by preventing its cytoplasmic phosphorylation and nuclear accumulation; ii) by 
promoting its nuclear dephosphorylation and export (Abate et al., 2004; Marshall and Geballe, 
2009). The role of pp65 in the counteraction of IFN activation was further supported by the 
observation that the transcription of IFN-β and several other IFN-stimulated genes (ISGs) was 
induced to a greater extent by the pp65 deletion mutant virus compared to wild type HCMV 
(Browne and Shenk, 2003). In addition, the overexpression of pp65 by an adenoviral vector 
inhibited the induction of MxA by IFN-α (Browne and Shenk, 2003).  
The other side of this complex scenario consists of different reports stating that pp65 does not 
mediate the HCMV evasion from the IFN response. For example, different authors (Browne and 
Shenk, 2003; DeFilippis et al., 2006; Taylor and Bresnahan, 2006), found that IRF3 relocalized in 
the same way to the nucleus after infection with wild type or pp65-mutant virus (pp65 deletion or 
pp65 stop mutants), in contrast to the results of Abate et al. (2004) (Abate et al., 2004). Instead, the 
absence of pp65 resulted in induction of IRF1 expression and nuclear accumulation of both IRF1 
and NF-κB (Browne and Shenk, 2003; Marshall and Geballe, 2009). A very recent work by Fu et al. 
(2017) partially supports the second idea, because another HCMV tegument protein, pp71, instead 
of pp65, has been identified as a negative regulator of STING-mediated induction of downstream 
antiviral genes and innate antiviral response (Fu et al., 2017). This observation could partially 
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explain the finding that a pp65 nonsense mutant virus, unlike the pp65 deletion virus, retained the 
capability to block the IFN-β induction (Taylor and Bresnahan, 2006); so it’s likely that the impact 
of the pp65 deletion might be mediated by a reduced expression of pp71, which in turn affects IE86 
expression and IFN evasion. The discrepancies among these studies could be explained by several 
factors. One variable that is seldom considered in experimental work with HCMV is variation 
among viral stocks. In particular, the ratio of pp65 between virions and dense bodies in viral 
preparations may vary widely (Jahn et al., 1987). Thus, differences in the dose of pp65 or other 
virion factors delivered to the cells in different studies might underlie some of the conflicting results 
(Marshall and Geballe, 2009). 
pp65 and inflammasome activation.  
The inflammasome is a key component of the innate immune system, and in these last few years, 
many advances have greatly increased our understanding of its macromolecular activation. The 
impact of pp65 on inflammasome activation has been evaluated (Huang et al., 2017), focusing on 
the system driven by the DNA sensor absent in melanoma 2 (AIM2). AIM2 is an interferon 
inducible protein involved in the foreign double-stranded DNA (dsDNA) recognition by a C-
terminal hematopoietic IFN-inducible nuclear (HIN) domain. Then, an N-terminal pyrin domain 
binds the adaptor molecule ASC and subsequently recruits pro-caspase-1 via CARD domain for its 
self-cleavage to form a functional inflammasome (Schattgen and Fitzgerald, 2011; Morrone et al., 
2015; Huang et al., 2017). Although the impact of AIM2-inflammasome to counteract HCMV 
infection remains to be fully elucidated, data suggests that the AIM2 HIN domain can recognize 
HCMV dsDNA through electrostatic interactions, regardless of the DNA sequence and GC content, 
but in a length-dependent manner (Morrone et al., 2015; Huang et al., 2017). These results are 
supported by the findings that HCMV infection induces the secretion of the pro-inflammatory 
cytokines IL-1β and IL-18, the products of inflammasome activation, in both the serum of renal 
transplant recipients who developed a primary HCMV infection, and in HCMV-infected gingival 
fibroblasts, respectively (Botero et al., 2008; van de Berg et al., 2010; Huang et al., 2017). In an in 
vitro recombinant model consisting of HEK293T cells expressing AIM2, ASC, pro-caspase-1, and 
pro-IL-1β, Huang et al. (2017) proposed that pp65 directly downregulates AIM2 inflammasome 
(Huang et al., 2017). In particular, pp65 binds to the cytoplasmic AIM2 early during infection, thus 
partially attenuating the AIM2 inflammasome proteins, followed by a reduction of caspase-1 and 
IL-1β activation (Figure 4). By contrast, Li et al. (2013) showed that pp65 bound the pyrin domain 
of all nuclear PYHIN proteins (IFI16, IFIX, and MNDA), but not the AIM2-PY domain (Li et al., 
2013). Notably, a pp65 deletion mutant HCMV strain is not able to induce a higher inflammasome 
activity compared to the wild type HCMV, as reflected by caspase-1 cleavage, thus further 
confirming the inhibitory activity on inflammasome activation (Li et al., 2013). Taken together, this 
data strength the controversial role of pp65 as a main player in the modulation of HCMV evasion 
mechanisms (Figure 4). 
CONCLUSIONS 
During millions of years of coevolution with the hosts, HCMV developed distinct strategies to 
counteract cellular defenses. The main player of HCMV evasion mechanisms against the innate 
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immune response is the tegument protein pp65, that act at different levels: i) early during infection 
pp65 interacts with and stabilizes IFI16 at the promoter of immediate-early genes, triggering an 
increase in IE protein expression, while later pp65/IFI16 interactome inhibits UL54 gene expression 
blocking HCMV replication; ii) pp65 interferes with the IFN pathway; iii) and with inflammasome 
activation. Collectively, these data underline the role of tegument protein pp65 as a critical 
molecular hub to evade the innate immune response induced by HCMV infection. 
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Figure 1 - Genes that encode representative tegument proteins along with commonly accepted 
protein names are shown. Data on relative abundance were obtained from Varnum et al. (Varnum 
et al., 2004). Phenotype refers to the ability of virus with a mutation in the indicated gene to 
replicate in human fibroblasts unless otherwise stated. Phenotypes are listed as augmenting (A), 
dispensable (D), or essential (E) for virus replication. Functions displays either demonstrated or 




Figure 2 - Schematic representation of the viral tegument protein pp65. Sequence revealed a 
conserved N-terminal Pyrin Association Domain (PAD) (yellow box), a divergent linker region 
(white box), and a conserved C terminus (CTD, ~90 residues) (brown box), indicating a bipartite 
structure. The conserved NLS motifs (KRRRHR/KKHR) are also shown. Numbers located above 




Figure 3 - Interplay between pp65 and IFI16 during HCMV infection. (A) Wild type infection 
allows maximal activation of the MIEP through efficient recruitment of IFI16 and probably NF-kB 
(dashed line) by pp65. (B) In the absence of IFI16, pp65 can still drive expression from MIEP, 
albeit less efficiently, perhaps through either a weaker interaction with or less efficient recruitment 
of NF-kB. (C) In the absence of pp65, IFI16 and NF-kB may still be capable of interacting at the 
MIEP, though MIEP expression is decreased indicating the requirement of pp65 for maximal 
expression. (D) Wild type infection allows maximal inhibition of the UL54 gene promoter through 
efficient recruitment of IFI16 by pp65. (B) In the absence of IFI16, pp65 can still drive expression 
from UL54 gene promoter, albeit less efficiently. (C) In the absence of pp65, and IFI16 may still be 
capable of interacting at the UL54 gene promoter, though UL54 gene promoter inhibition is absent 




Figure 4 - Model for the functional role of pp65 in modulating IFNs and inflammasome signaling 
during HCMV infection. 
 
